Aurobindo Pharma Limited has informed the Exchange about General Updates
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma's wholly owned subsidiary CuraTeQ Biologics has received marketing authorisation from CDSCO for Bevqolva®, a bevacizumab biosimilar. The drug is indicated for metastatic carcinoma of the colon or rectum (colorectal cancer). The authorisation permits manufacturing at CuraTeQ's Hyderabad facility with two presentations: 100 mg/4 mL and 400 mg/16 mL vials. This marks Aurobindo's entry into the biosimilar segment for oncology treatment, expanding beyond its existing generic pharmaceutical portfolio.
This regulatory approval represents a positive development for Aurobindo as it diversifies into biosimilars, a growing segment in the pharmaceutical industry. It could contribute to future revenue streams once the product is commercialised in the Indian market.